Xoifeb 80 Tablet contains Febuxostat 80 mg, a xanthine oxidase inhibitor indicated for the management of hyperuricemia in patients with gout. Febuxostat works by selectively inhibiting xanthine oxidase, an enzyme responsible for converting hypoxanthine to xanthine and xanthine to uric acid, thereby reducing serum uric acid levels. This reduction helps prevent gout flares, tophi formation, and renal complications associated with chronic hyperuricemia. Xoifeb 80 is typically prescribed for patients who are intolerant to or inadequately managed with allopurinol. The tablet should be administered orally, once daily, with or without food, and dosage adjustments may be necessary based on renal function and therapeutic response. Common adverse effects include liver function abnormalities, nausea, rash, and headache; therefore, periodic monitoring of liver enzymes and renal function is recommended during therapy. Febuxostat is contraindicated in patients with hypersensitivity to the drug and should be used cautiously in individuals with cardiovascular disease due to a potential increased risk of cardiovascular events. Patients are advised to maintain adequate hydration and avoid alcohol consumption to minimize the risk of kidney stones. Xoifeb 80 Tablet offers an effective therapeutic option for long-term management of gout by maintaining target serum urate levels and preventing disease progression.